Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

NOXOPHARM LIMITED

INVESTOR PRESENTATION - NOXOPHARM LIMITED

ASX:NOX

NOXOPHARM LIMITED

Health Care

Noxopharm Limited (ASX:NOX) is a clinical-stage oncology drug development company. Noxopharm operates in the healthcare sector, specifically in the area of drug development. The Company has a primary focus on the development of Veyonda®, a clinical stage drug designed to enhance the effectiveness and safety of chemotherapy and radiotherapy.

Read more

Market Cap

83.16m

Price at Close

$0.39

4w avg. Volume

758.77k

4w avg. Turnover

$275.86k

Announcements
announcementt+2 movementdate
  • Noxopharm Corporate Presentation September 2020

    Periodic Reports

  • +4.88%

    20 Sep 2020

+4.88%

20 Sep 2020
  • Noxopharm Appoints US Corporate Advisory and Consulting Firm

    Company Administration

  • +7.69%

    18 Sep 2020

+7.69%

18 Sep 2020
  • Notification of Date of 2020 Annual General Meeting

    Notice Of Meeting

  • +11.43%

    16 Sep 2020

+11.43%

16 Sep 2020
  • Annual Report to shareholders

    Periodic Reports

  • +12.90%

    14 Sep 2020

+12.90%

14 Sep 2020
  • Appendix 4G and Corporate Governance Statement

    Periodic Reports

  • +12.90%

    14 Sep 2020

+12.90%

14 Sep 2020
  • Noxopharm Appoints New Chair

    Company Administration

  • +3.39%

    08 Sep 2020

+3.39%

08 Sep 2020
  • Global CRO To Execute DARRT-2 Prostate Cancer Study

    Progress Report

  • +3.39%

    07 Sep 2020

+3.39%

07 Sep 2020
  • Veyonda COVID-19 Study Approved For Immediate Start

    Progress Report · Market sensitive

  • +3.28%

    31 Aug 2020

+3.28%

31 Aug 2020
  • Final Director's Interest Notice - ID

    Shareholder Details

  • +3.28%

    31 Aug 2020

+3.28%

31 Aug 2020
  • Appendix 4E and Audited Financial Statements FY2020

    Periodic Reports · Market sensitive

  • +3.28%

    31 Aug 2020

+3.28%

31 Aug 2020
Market Data

Current Price

$0.39

52WK HIGH

$0.47

52WK LOW

$0.095

1YR RETURN

-3.70%

1YR RETURN VS. SECTOR

-31.98%

90 DAY RETURN

+105.26%

ASX RANK

840

/2,016

SECTOR RANK

18

/47

SHARES OUTSTANDING

213.24m
ASX:NOX

NOXOPHARM LIMITED

Health Care

Noxopharm Limited (ASX:NOX) is a clinical-stage oncology drug development company. Noxopharm operates in the healthcare sector, specifically in the area of drug development. The Company has a primary focus on the development of Veyonda®, a clinical stage drug designed to enhance the effectiveness and safety of chemotherapy and radiotherapy.

Read more

Market Cap

83.16m

Price at Close

$0.39

4w avg. Volume

758.77k

4w avg. Turnover

$275.86k

ASX:NOX is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.